San Antonio, TX, --- July 23, 2009 – OncoVista Innovative Therapies, Inc. (“OncoVista”) (OTC BB: OVIT.OB)  and AdnaGen AG announced that The University of Texas M. D. Anderson Cancer Center will collaborate on clinical studies of AdnaGen’s molecular based CTC technology in Women with High-Risk Locally Advanced Breast Cancer (LABC) that have completed Neoadjuvant and Local Therapy.

“M. D. Anderson is dedicated to helping develop novel approaches that may improve the prognosis of patients with malignant diseases,” said Dr. Massimo Cristofanilli, Associate Professor of Medicine and the Director of the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic. Dr. Cristofanilli added “We are dedicated to improving the prognosis of patients with advanced breast cancer, including inflammatory breast cancer (IBC).”

“We are excited that one of the world’s most renowned cancer centers will conduct clinical trials for the AdnaGen Breast Select & Detect molecular based CTC technology” said Alexander Weis, PhD, Chief Executive Officer of OncoVista and AdnaGen. “This collaboration will further explore the utility of the AdnaGen technology in the treatment of various stages of breast cancer and its potential for becoming a highly effective diagnostic tool.”

About OncoVista, Inc.

OncoVista is a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies which are more efficacious and less toxic. For further information about OncoVista, please visit www.oncovista.com. OncoVista, Inc. is the majority owner of AdnaGen, AG.

About AdnaGen AG

AdnaGen is a privately-held biotechnology company based in Langenhagen, Germany. AdnaGen was recently acquired by OncoVista, Inc. and is now a part of an integrated healthcare organization. AdnaGen offers test systems  that facilitate a personalized approach to treatment of cancer. AdnaGen´s core expertise is the development of innovative tumor diagnostics by utilizing its proprietary technology for the detection and molecular analysis of biomarkers in circulating tumor cells (CTC). Kits for breast (AdnaTest BreastCancer), colon (AdnaTest ColonCancer) and prostate cancer (AdnaTest ProstateCancer) as well as an add-on kit for the detection of steroid receptors (AdnaTest ER/PR) on CTC are CE-marked and currently marketed in Europe. AdnaGen is ISO 9001 and EN 13485 certified. For more information, go to www.adnagen.com 

About The University of Texas M. D. Anderson Cancer Center

Since 1944, nearly 800,000 patients have turned to M. D. Anderson for cancer care in the form of surgery, chemotherapy, radiation therapy, immunotherapy, or combinations of these and other treatments. This multidisciplinary approach to treating cancer was pioneered at M. D. Anderson. Because its experts focus on cancer, they are renowned for their ability to treat all types of cancer, including rare or uncommon diseases. M. D. Anderson employs more than 16,000 people, including more than 1,400 faculty members. More information on M. D. Anderson may be found at www.mdanderson.org 

Forward-Looking Statements: A number of statements contained in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. These risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements.